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Abstract
The effects of highly active antiretroviral therapy (HAART) on progression of hepatic fibrosis in HIV-hepatitis C virus (HCV)
co-infection are not well understood. Deaths from liver diseases have risen in the post-HAART era, yet some cross-sectional
studies have suggested that HAART use is associated with improved fibrosis rates. In a retrospective cohort of 533 HIV
mono-infected and 127 HIV/HCV co-infected patients, followed between January 1991 and July 2005 at a university-based
HIV clinic, we investigated the relationship between cumulative HAART exposure and hepatic fibrosis, as measured by the
aspartate aminotransferase-to-platelet ratio index (APRI). We used a novel methodological approach to estimate the dose-
response relationship of the effect of HAART exposure on APRI. HAART was associated with increasing APRI over time in
HIV/HCV co-infected patients suggesting that they may be experiencing cumulative hepatotoxicity from antiretrovirals. The
estimated median change (95% confidence interval) in APRI per one year of HAART intake was of 20.46% (21.61% to
0.71%) in HIV mono-infected compared to 2.54% (21.77% to 7.03%) in HIV/HCV co-infected patients. Similar results were
found when the direct effect of HAART intake since the last visit was estimated on the change in APRI. HAART use
associated is with increased APRI in patients with HIV/HCV co-infection. Therefore treatment for HCV infection may be
required to slow the growing epidemic of end-stage liver disease in this population.
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Introduction
Since the advent of highly active antiretroviral therapy
(HAART) there have been dramatic reductions of morbidity and
mortality from virtually all causes among HIV-infected per-
sons.[1,2] One of the glaring exceptions to this trend is liver-
related deaths which now represent one of the leading causes of
death among HIV-infected individuals.[3–8] Much of this excess
mortality has been driven by the epidemic of Hepatitis C (HCV)
co-infection affecting more than 30% of HIV-infected patients in
developed countries.[9,10] HCV progresses more rapidly in
patients co-infected with HIV.[11–13] In addition, non-alcoholic
steato-hepatitis is increasingly being recognized as an important
cause of liver disease in HIV-infected persons which may
contribute to liver-related morbidity in the absence of HCV
infection.[14]
A number of cross-sectional studies have suggested that
HAART, especially regimens containing protease inhibitors (PI)
[15–17], is associated with improved fibrosis rates. Other studies
have observed no benefit.[18,19] While it may be argued that
increasing rates of liver outcomes is simply the ‘‘unmasking’’ of
liver disease as individuals survive longer with HAART, other
factors may be at play including irreversible hepatic damage,
incomplete immune recovery, and chronic hepato-toxicity related
to HAART. The net effect of HAART on liver disease therefore
remains unclear.
The aspartate aminotransferase (AST) to platelet ratio index
(APRI) has been validated as a surrogate marker of significant
hepatic fibrosis in HIV/HCV co-infection.[20–22] We recently
reported that the APRI was predictive of the development end-
stage liver disease in HIV/HCV co-infection.[23] We used the
APRI to evaluate the progression of liver disease in HIV-infected
patients with and without HCV using standard linear regression
models. We further evaluated the effect of HAART on liver
disease progression and found that cumulative exposure, partic-
ularly to protease inhibitor-based regimens, was associated with
increasing fibrosis in HIV/HCV co-infected patients and, to a
lesser but nevertheless significant extent, in patients infected with
HIV only.[23] For example, the estimated adjusted increase in
slope of lnAPRI attributable to one year of HAART exposure was
0.18 vs. 0.07 units over 3 years in HIV/HCV co-infected and
HIV-infected patients, respectively.
In this paper, we use an extension of propensity scores
methodology to adjust for potentially confounding variables so
as to evaluate whether HAART plays a role in liver disease
progression in HIV-infected patients with and without HCV by
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exposure.
Methods
Study design and setting
This is a retrospective cohort study from a university-based
clinic serving approximately 1000 active HIV-infected patients.
Since 1989, a computerized database on all patients has been
maintained into which demographic data, clinical diagnoses (both
AIDS and non-AIDS), laboratory and prescription information
are prospectively entered. Any changes in antiretroviral medica-
tions are reviewed at each clinic visit by a physician and/or clinic
pharmacist and recorded. This study was approved by the
Institutional Research Ethics Board. As this was a retrospective
review of electronic records, we did not obtain informed consent
from study participants, in accordance with regulations of our
intuitional ethics review board which approved the study.
All participants were HIV sero-positive (determined by positive
ELISA with confirmatory Western blot), attended the clinic at
least twice between January 1991 and December 2004, and did
not have a clinical diagnosis of cirrhosis at baseline. Subjects were
categorized by HIV/HCV co-infection or by HIV infection alone.
Patients with both HCV and chronic hepatitis B virus infections
were excluded. HCV testing was performed using ELISA followed
by confirmatory testing of positive samples with recombinant
immuno-blot assays. Patients were followed until July 2005 or
censored on their last clinic visit if lost to follow-up. Ten patients
were censored when they received specific HCV therapy and a
further 13 were excluded from the analysis due to missing
information at each visit on at least one variable of interest. The
analyzed cohort was thus comprised of 660 subjects monitored
over 14 years: 533 who were HIV infected and 127 who were co-
infected with HCV.
Baseline demographic, clinical and laboratory variables, as well
as follow-up data for 6-month intervals, were extracted from the
database. Concurrent measures (taken not more than 7 days apart)
of AST and platelets were used to calculate APRI values. For each
6-month interval the most recent APRI value was used. CD4+ T-
cell counts were measured by flow cytometry. Plasma HIV viral
load measurements were performed using Chiron branched chain
DNA assays (standardized to Quantiplex version 3.0 equivalent as
previously described[24]).
Exposure and covariate assessment
The exposure of interest was HAART intake, calculated as the
total number of years on HAART up to the last APRI
measurement in each interval. HAART was defined as at least
three antiretrovirals taken concurrently for more than one day.
Triple nucleoside regimens were considered as HAART if they
contained abacavir. We considered the following variables that
may confound the relationship between HAART and liver
function: age, gender, region of birth, transmission risk factors
(men who have sex with men (MSM) and injection drug use),
calendar year at study entry, use of HAART prior to baseline,
CD4+ T-cell counts, CD8+ T-cell counts, and plasma HIV RNA
(log copies/ml). CD4 and CD8 counts and HIV RNA were
measured at follow-up visits and were therefore time-varying.
Outcome assessment
The outcome of interest was the natural logarithm of the APRI
(lnAPRI). The APRI was defined as: 1006(AST/upper limit of
normal)/platelet count (10
9/l).[25] An APRI score.1.5 has been
shown to be predictive of significant fibrosis (defined as an Ishak
score greater than 3) with an the area under the ROC of 0.76–
0.85.[21,22,25] Thus, we used the established cutoff of 1.5 to
determine the presence of significant fibrosis at baseline and at the
last visit. Similarly, an APRI,0.5 has been shown to rule out the
presence of fibrosis[25] and was used to define its absence. The log
of the APRI, a transformation which nearly normalizes the
distribution, was used in all analyses however results are reported
for APRI to facilitate clinical interpretation. Baseline was defined as
the date of the first APRI measure, which generally occurred within
one month of the first clinic visit. The response, lnAPRI, is not a
health outcome typically considered by treating physicians and is
not used in clinical practice to inform treatment decisions with
respect to HAART; see Figure 1 for the postulated causal diagram.
Statistical methods
We focused on the relationship between HAART and liver
function. We began by examining change in lnAPRI between clinic
visits caused by the dose of HAART received in that time, that is, we
examined the direct or ‘‘cross-sectional’’ effect of most recent
HAART intake on the change in APRI (see Figure 1). This gave rise
to a longitudinal data model that assumes a repeated measures
structure, where each participant provided a time-series of
measurements both for the outcome, change in lnAPRI, for the
exposure of interest, HAART intake since the last visit, and for time-
varying covariates, i.e., CD4+ T-lymphocyte count, CD8+ T-
lymphocyte count, and HIV RNA. We used an extension of the
propensity scores approach, the Generalized Propensity Score
(GPS)[26–28] that has been broadened to the repeated measures
data scenario (as described in Estimation of Dose-Response Functions for
Longitudinal Data using The Generalized Propensity Score by EEM Moodie
and DA Stephen (2009), manuscript in revision) to estimate the
marginaldose-responsecurvetomodeltheeffectofHAARTonliver
function as measured by the lnAPRI. For details, see Appendix S1.
As not all subjects had used HAART at all points in the study, the
predictive model for treatment, i.e. the GPS, needed to acknowl-
edge that the nature of the dose distribution was a mixture of a mass
at zero dose and a continuous distribution. Estimation of the density
of cumulative HAART is straightforward if a parametric form for
the continuous part of the distribution is assumed. We used a Box-
Cox transformation of positive cumulative doses with power
parameter selected by maximum likelihood to render the data
more approximately normal.[29] The transformed doses were
modeled under a normal density whose mean was a linear function
of age, sex, region of birth, year of study entry, use of HAART prior
to baseline, time in cohort, co-infection status, injection drug use,
MSM, CD4+ T-cell counts, CD8+ T-cell counts, and HIV RNA, as
well as interactions between co-infection status and each of CD4+
T-cell count, HIV RNA, injection drug use, and MSM. To estimate
the probability of having a non-zero dose of cumulative HAART in
any interval, a logistic model to the binary (HAART=0,
HAART.0) dose data was used, including the same predictors
are in the continuous-dose portion of the mixture distribution. We
further explored the relationship between HAART and liver
function by examining the lnAPRI at each clinic visits as a function
of the dose of HAART received up to that time.
Secondary analyses
To explore differences between PI-based HAART and non-
nucleoside reverse transcriptase inhibitors (NNRTI)-based
HAART, two additional GPS analyses were conducted. In
addition to the variables included in the main analyses (see
above), we also included cumulative NNRTI use in the analysis of
the effects of PI on APRI, and similarly included cumulative PI use
when analyzing the effects of NNRTI on APRI. We also
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patients without significant fibrosis at baseline (i.e. APRI,1.5).
Results
Baseline characteristics of study subjects
The cohort contained information from 4496 visits (3718 from
mono-infected and 778 from co-infected patients) with complete
information on CD4+ T-cell counts, CD8+ T-cell count, HIV
RNA, and lnAPRI from 660 HIV patients. A total of 533 patients
were infected with HIV alone and 127 were co-infected with
HCV. A non-negligible proportion of the cumulative HAART
intake measurements (906/4496 or 20%) reported no intake.
The duration of follow-up was comparable between the mono-
and co-infected groups. Baseline characteristics of the subjects are
shown in Table 1. Mean CD4+ T-cell counts were higher in co-
infected than mono-infected patients and, on average, CD8+ T-
cell counts were higher and viral loads were lower in patients with
HIV alone. The most striking difference between the two patient
groups was history of MSM, which was more frequent in the
mono-infected group, and of injection drug use, which was
predominant in the co-infected patients. The majority of the
cohort in both patient populations was born in Canada; however,
the proportion was much higher in the co-infected (83.5%) than
mono-infected (58.0%) patients.
The baseline prevalence of significant fibrosis (APRI.1.5) was
3.9% (21/533) in HIV mono-infected patients and 17.3% (22/127)
of HIV/HCV co-infected patients. The proportions of patients with
APRI,0.5 atbaseline were77.7%(414/533)ofHIV mono-infected
patients and 43.3% (55/127) of HIV/HCV co-infected patients.
The direct effect of HAART use on liver disease
progression
Exploratory plots of lnAPRI by cumulative HAART intake
suggested a positive relationship (Figure 2). The GPS and time in
the cohort not on HAART were included in a linear mixed model
with cumulative HAART, which also allowed for modification of
the effect of HAART by co-infection status.
Analyses of the effect of HAART consumed since last clinic visit
on liver fibrosis progression was performed in a subset of the full
cohort (subjects were required to have at least two clinic visits for
changes in dose and lnAPRI measurements to be recorded);
baseline characteristics are summarized in Table 2. The estimated
causal dose-response curve was lower than we previously
reported[23]; in fact, no significant change in APRI was found
to be caused by HAART intake in people infected with HIV alone
and only a small increase was observed in co-infected individuals
(Figure 3). The response to dose since the last clinic visit found no
significant change in APRI caused by HAART intake in people
infected with HIV alone. An increase was observed in co-infected
individuals (Figure 3). Among mono-infected persons, the median
increase in APRI attributable to one year of HAART intake was
approximately 0.04% (95% CI: 23.88 to 4.12) compared to
6.05% (95% CI: 21.82 to 14.15) in co-infected populations.
Relating cumulative HAART use to liver disease
progression
Patterns of APRI response to cumulative HAART were similar to
those found in the estimation of the direct of effects of most recent dose
on changes in APRI (Figure 4). Among mono-infected persons, the
median increase in APRI attributable to one year of HAART intake
was approximately 20.46% (95% CI: 21.61% to 0.71%) compared
to 2.54% (95% CI: 21.77% to 7.03%) in co-infected populations.
Thus, over five years we would expect to see an increase in the median
APRI of approximately 13.35% (95% CI: 28.52% to 140.47%) in
HIV/HCV-infected populations. Unsurprisingly, the median APRI
of the mono- and co-infected individuals differed considerably in the
absence of HAART use: estimated APRI under no intake of HAART
was 0.32 (95% CI: 0.31 to 0.34) in the HIV-only cohort and 0.54
(95% CI: 0.53 to 0.55) in the HIV/HCV-infected group.
Figure 1. Postulated causal diagram. A directed acyclic graph of the relationship between HAART exposure and APRI over time, where
potentially confounding variables such as, for example, CD4+ T-cell counts, are represented by X. The Generalized Propensity Score permits unbiased
estimation of the direct (or cross-sectional) effect, a, of most recent HAART intake on the response.
doi:10.1371/journal.pone.0004517.g001
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Several additional analyses were undertaken to further explore
the effect of HAART on APRI. We explored of the effects of
cumulative PI and NNRTI on APRI. The median increase in
APRI per one year of PI intake was 0.47% (95% CI: 20.99% to
1.86%) in HIV mono-infected as compared to 3.31% (95% CI:
22.09% to 9.02%) in HIV/HCV co-infected patients. The
median increase in APRI per one year of NNRTI intake was
0.55% (95% CI: 21.26% to 2.38%) in HIV mono-infected as
compared to 2.18% (95% CI: 26.53% to 11.69%) in HIV/HCV
co-infected patients. This confirms the previous results which
suggested that increased APRI on HAART may be more
attributable to PI use than NNRTI use.
The sub-group analysis focusing on patients without significant
fibrosis at baseline was performed on 4242 observations in 647
individuals. The median increase in APRI per one year of HAART
intake was 0.48% (95% CI: 20.61% to 1.59%) in HIV mono-
infected as compared to 3.44% (95% CI: 20.92% to 7.98%) in
HIV/HCV co-infected patients, indicating that the relationship
observed between HAART and APRI is not driven by the sub-set of
patients with significant fibrosis at the start of the study.
Discussion
To date, the study of the effects of HAART on liver fibrosis over
time has been limited primarily to mathematical models based on
single measurements of liver fibrosis. No previous study has
focused on repeated balancing of patient covariates over time in
order to estimate dose-response curves.
Our study used a large clinical cohort with data collection and
follow-up spanning over a decade. With the availability of detailed
clinical and laboratory information, we were able to adjust for
many potential baseline and follow-up confounders. In addition,
care was taken to ensure that the impact of time, both in terms of
the duration of HIV infection and calendar time, was taken into
account in the analysis. We have thus shown that HAART
appears to have a negligible effect on liver fibrosis progression as
measured by the APRI in HIV-infected patients, but is associated
with an increase in fibrosis progression in HIV/HCV co-infected
individuals. This finding contrasts somewhat with our previous
results obtained using standard mixed models where we observed
that HAART was associated with fibrosis progression in both
groups.[23]
Potential limitations of the present study
As with all models for observational data, approaches such as
the GPS require assumptions to be appropriately specified.[30,31]
The GPS approach has been shown to be a powerful tool in the
analysis of direct effects of continuous dose in cross-sectional[28]
and longitudinal data (Estimation of Dose-Response Functions for
Longitudinal Data using The Generalized Propensity Score by EEM
Moodie and DA Stephen (2009)) however the methodology does
not control for unmeasured confounding variables. Diagnostic
plots (not shown) suggested that the constructed GPS appropri-
ately broke the confounding relationships for those variables that
were recorded. It is nevertheless possible that estimates are
confounded by factors for which data were unavailable such as
alcohol use, the presence of other infections, and the use of hepato-
Table 1. Baseline characteristics according viral co-infection status.
HIV mono-infected (n=533) HIV/HCV co-infected (n=127)
Length of follow-up (months) 36.3 (0, 169.4) 31.8 (0, 146.3)
Number of visits 1–5 261 (50.0) 67 (52.8)
6–10 149 (28.0) 39 (30.7)
.10 123 (22.0) 21 (18.5)
Age (years) 37.7 (18, 72.7) 37.4 (19.5, 63.5)
Sex (male) 396 (74.3) 94 (74.0)
Region of birth Africa 94 (17.6) 7 (5.5)
Asia 6 (1.1) 2 (1.6)
Canada 309 (58.0) 106 (83.5)
Europe 29 (5.4) 9 (7.1)
Haiti 71 (13.3) 1 (0.8)
Latin America/Caribbean 24 (4.4) 2 (1.6)
Intravenous drug use 12 (2.3) 94 (74.0)
Males with history of sex with men 281 (52.7) 14 (11.0)
Year of study entry 1991–1995 91 (17.1) 19 (15.0)
1996–2000 217 (34.1) 61 (41.7)
2000–2004 225 (48.8) 47 (43.3)
CD4+ T-cell count (610
9 cells/ml) 227 (0, 1753) 290 (2, 1017)
CD8+ T-cell count (610
9 cells/ml) 706 (0, 4919) 600 (0, 2190)
Plasma HIV RNA (log copies/ml) 3.98 (1.70, 6.59) 4.19 (1.70, 6.09)
APRI 0.31 (0.05, 11.43) 0.59 (0.13, 20.85)
Prior use of HAART 182 (34.1) 39 (30.7)
For continuous variables, statistics reported are median (range). For categorical variables statistics reported are count (%).
Abbreviations: APRI, AST to platelet ratio index; HAART, highly active antiretroviral therapy; HCV, hepatitis C infection.
doi:10.1371/journal.pone.0004517.t001
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heavily are less likely to maintain a HAART regimen than patients
who do not consume alcohol. Under this assumption, our results
likely underestimate the increase in APRI caused by HAART use.
Future work will include an analysis of a prospective co-infection
cohort on whom alcohol intake information is available.
A further complication of longitudinal data such as these is that
time-varying variables such as CD4 cell counts could potentially
act as mediating variables in addition to being confounding
variables. In such cases, when the total (direct and indirect) effect
of cumulative dose is to be estimated, the use of marginal
structural models is typically preferred over adjusting for such
variables in a regression model, which is, in effect, the result of the
GPS approach. However in the present study, the highly varied
number of visits per individual in the study (recall that
approximately 50% of individuals present for five visits or fewer
while one fifth of the participants present to more than 10) and the
absence of a biologically meaningful baseline time make the
marginal structural model approach less appealing. Furthermore,
the implementation of the inverse weighting required for marginal
structural models is not straightforward when dose densities are
mixtures distributions with continuous components, as in the
present study.
We therefore proceeded with the GPS analysis, and were
reassured by the concordance of conclusions between the
estimation of the direct effect of HAART intake since the last
visit on change in APRI and the analysis that examined the effects
of cumulative HAART on APRI. We note that the primary
analysis which investigated the effect of HAART received between
two clinic visits on the change in APRI between the two visits after
intake of that HAART does in fact provide an estimate of causal
parameter. However in the analysis in which we considered the
effect of cumulative HAART on APRI, the relationship estimated
captures a combination of the effect of the most recent dose of
HAART and additionally the effect of HAART consumed at
previous intervals that is not mediated through the time-varying
confounding variables. We suspect that this leads to an
underestimate of the total effect of cumulative HAART intake
on liver function, however this relationship is difficult to surmise as
the interactions between immunological factors such as lympho-
cyte counts and viral load on the components of the APRI are not
fully understood.
Another potential limitation of our study was the use of APRI as
a surrogate marker for liver fibrosis. Both AST and platelets may
be subject to variations due to factors other than liver disease
progression. Ideally, the evolution of hepatic fibrosis would be
assessed by multiple liver biopsies in a large cohort. However, the
acceptability, cost, and risk associated with multiple biopsies make
such a study impractical. Liver biopsy itself is an imperfect
measure as it is subject to high sampling variability[32] and
Figure 2. APRI by cumulative HAART exposure in years over the course of the study. The figure on the left is HIV-infected and on the right
is the HIV/HCV co-infected patients; 15 data points in mono-infected persons and 39 points in co-infected persons have APRI scores above 4.0.
doi:10.1371/journal.pone.0004517.g002
Table 2. Baseline characteristics according viral co-infection status (individuals used to assess the by-interval effects).
HIV mono-infected (n=533) HIV/HCV co-infected (n=127)
Length of follow-up (months) 43.4 (1.6, 169.4) 38.3 (0.9, 146.3)
Number of visits 1–5 296 (56.7) 66 (55.5)
6–10 130 (24.9) 37 (31.1)
.10 96 (18.4) 16 (13.4)
Age (years) 37.7 (18.1, 72.7) 37.6 (19.5, 63.5)
Sex (male) 389 (74.5) 89 (74.8)
Region of birth Africa 91 (17.4) 7 (5.9)
Asia 6 (1.1) 2 (1.7)
Canada 305 (58.4) 99 (83.2)
Europe 28 (5.4) 9 (7.6)
Haiti 68 (1303) 1 (0.8)
Latin America/Caribbean 24 (4.6) 1 (0.8)
Intravenous drug use 12 (2.3) 89 (74.8)
Males with history of sex with men 276 (52.9) 13 (10.9)
Year of study entry 1991–1995 86 (16.5) 16 (13.4)
1996–2000 214 (41.0) 57 (47.9)
2000–2004 222 (42.5) 46 (38.7)
CD4+ T-cell count (610
9 cells/ml)
CD8+ T-cell count (610
9 cells/ml) 728 (0, 4141) 592 (0, 1845)
Plasma HIV RNA (log copies/ml) 3.18 (1.70, 6.00) 3.18 (1.70, 5. 29)
APRI 0.30 (0.08, 6.84) 0.57 (0.12, 19. 65)
Prior use of HAART 179 (34.13) 38 (31.9)
For continuous variables, statistics reported are median (range). For categorical variables statistics reported are count (%).
Abbreviations: APRI, AST to platelet ratio index; HAART, highly active antiretroviral therapy; HCV, hepatitis C infection.
doi:10.1371/journal.pone.0004517.t002
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assessment of the biopsy.[33] Therefore, in the absence of even a
perfect invasive reference standard, non-invasive markers are
more appealing to clinicians and patients alike. Non-invasive
measures of liver fibrosis are gaining acceptance for long-term
evaluation of hepatic complications in HCV co-infection.[34] The
APRI compares favorably with other non-invasive biomarkers
such as the FIB-4[35], the MULTIVIRC equation[36], and the
Forns index[37] that do not incorporate the same parameters.
Conclusions
We found that the APRI was not increased by long-term
HAART use in patients infected with HIV alone, but was
associated with increased APRI in patients with HIV/HCV co-
infection. As HAART appears to increase fibrosis progression in
HIV/HCV co-infected patients possibly through cumulative
hepato-toxicity, specific treatment for HCV infection will be
required to slow the growing epidemic of end-stage liver disease in
this population.
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Figure 3. Estimated dose-response function: change in APRI due to HAART intake between clinical visits. The plot includes point-wise
95% confidence bands for HIV mono-infected patients (solid line) and HIV/HCV co-infected patients (dashed line).
doi:10.1371/journal.pone.0004517.g003
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